ERBB2 and neoplasm: In canine transitional cell carcinoma, lapatinib inhibits the phosphorylation of HER2 and cell tumor growth in vitro and reduces the tumor volume in vivo, suggesting that the molecular target also exerts its role in dogs, inhibiting HER2 signaling and inducing cell cycle arrest [37].